Incretin-Based Therapies and the Associated Impact on Bone Health
Open Access
- 16 September 2026
- journal article
- Published by IMR Press in International Journal of Pharmacology
- Vol. 22 (5)
Abstract
Incretin-based therapies are being increasingly used in the treatment of type 2 diabetes mellitus and obesity, both of which are associated with impaired bone quality, altered skeletal remodeling, and increased fracture risk. Experimental studies suggest that incretin signaling may affect bone through osteoblast and osteoclast activity, Wnt/β-catenin signaling, adipose tissue inflammation, metabolic regulation, and the gut–bone axis. However, clinical evidence remains heterogeneous, with most studies indicating neutral or context-dependent effects on bone mineral density and fracture risk rather than consistent skeletal benefit. Interpretation is further complicated by treatment-induced weight loss, changes in lean mass and mechanical loading, diabetes-related skeletal fragility, and the limited number of trials specifically designed to assess bone endpoints. Evidence for newer dual and triple agonists is especially limited, despite their growing use and substantial weight-loss effects. Incretin-based therapies appear reassuring from a skeletal safety perspective; however, long-term studies with dedicated skeletal endpoints are needed to determine their effects on bone quality, falls, and fracture risk in high-risk populations. This review summarizes current mechanistic, preclinical, and clinical evidence on the effects of glucagon-like peptide-1 receptor agonists, dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors on bone turnover, bone mineral density, bone quality, and fracture outcomes.Keywords
This publication has 78 references indexed in Scilit:
- Prescribing Trends of Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes or ObesityJAMA Network Open, 2025
- GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trialsObesity, 2024
- Bone Health After Exercise Alone, GLP-1 Receptor Agonist Treatment, or Combination TreatmentJAMA Network Open, 2024
- Effects of Incretin Therapy on Skeletal Health in Type 2 Diabetes—A Systematic ReviewJBMR Plus, 2023
- Incretin hormones and type 2 diabetesDiabetologia, 2023
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- The association between type 2 diabetes mellitus, hip fracture, and post-hip fracture mortality: a multi-state cohort analysisOsteoporosis International, 2019
- Fracture Risk After Roux-en-Y Gastric Bypass vs Adjustable Gastric Banding Among Medicare BeneficiariesJAMA Surgery, 2019
- The effects of weight loss approaches on bone mineral density in adults: a systematic review and meta-analysis of randomized controlled trialsOsteoporosis International, 2016
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Prevents Osteopenia by Promoting Bone Formation and Suppressing Bone Resorption in Aged Ovariectomized RatsJournal of Bone and Mineral Research, 2013